Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 16/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990050 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HPGDGRM5KMT2AL3MBTL1 | |
| SCHEMBL4507971 | 0.92 | GRM5 (0.44) | ALDH1A1HPGDGRM5KMT2AL3MBTL1 | |
| SCHEMBL990107 | 0.90 | ALDH1A1 (0.49) | ALDH1A1HPGDGRM5KMT2AL3MBTL1 | |
| SCHEMBL990808 | 0.90 | ALDH1A1 (0.49) | ALDH1A1HPGDGRM5KMT2AL3MBTL1 | |
| SCHEMBL990781 | 0.89 | ALDH1A1 (0.48) | ALDH1A1HPGDGRM5KMT2AL3MBTL1 | |
| SCHEMBL990810 | 0.89 | ALDH1A1 (0.48) | ALDH1A1HPGDGRM5KMT2AL3MBTL1 | |
| SCHEMBL989481 | 0.85 | GRM5 (0.47) | GRM5 | |
| SCHEMBL990155 | 0.85 | GRM5 (0.47) | GRM5 | |
| SCHEMBL990930 | 0.84 | GRM5 (0.47) | GRM5 | |
| SCHEMBL991428 | 0.84 | GRM5 (0.47) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137206-A1 | PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| EP-2320892-A2 | COMBINATION PRODUCTS | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |